Picture of Aptamer logo

APTA — Aptamer News Story

0.000.00%
gb flag iconLast trade - 00:00
HealthcareHighly SpeculativeMicro CapSucker Stock

Investor Webinar

RNS Number : 4492T

Aptamer Group PLC

31 July 2025

 

 

31 July 2025

 

Aptamer Group plc

 

("Aptamer", the "Company" or the "Group")

 

Investor Webinar

 

Aptamer Group plc (AIM: APTA), the leading developer of next-generation synthetic binders delivering innovation to the life science industry, announces that Dr Arron Tolley, Chief Executive Officer, and Andrew Rapson, Chief Financial Officer, will be hosting an investor webinar on Thursday, 7 August 2025, at 6:00 p.m. (BST).

 

The webinar will principally cover the Company's recent progress, focusing on developments highlighted in the Trading Update released by the Company at 07:00 today.

 

There will be a Q&A session for investors after the presentation, and questions can be submitted pre-event as part of the registration process.

 

The webinar is open to shareholders and other interested parties who can register for the event by using the following link: https://www.turnerpope.com/register/

 

The webinar will be chaired by experienced news and corporate events presenter Katie Pilbeam (www.katiepilbeam.com) and hosted by the Company's broker, Turner Pope Investments.

 

- Ends -

 

For further information, please contact: 

Aptamer Group plc
Dr Arron Tolley, Chief Executive Officer
+44 (0) 1904 217 404
SPARK Advisory Partners Limited - Nominated Adviser
Andrew Emmott / Jade Bayat
+44 (0) 20 3368 3550
Turner Pope Investments (TPI) Limited - Broker
James Pope / Andrew Thacker
+44 (0) 20 3657 0050
Northstar Communications Limited - Investor Relations
Sarah Hollins
+44 (0) 113 730 3896
  About Aptamer Group Aptamer Group is a leading developer of next-generation synthetic binders delivering innovation to the life sciences industry. The Group develops Optimer® binders, advanced molecules that work like antibodies by attaching to specific targets in the body. These binders are used in medicine, diagnostic tests, and research tools, offering benefits like high stability, reliable performance, and lower costs compared to traditional antibodies.   Aptamer operates a fee-for-service business in the US$210 billion market for antibody alternatives, working with all top 10 global pharmaceutical companies. It is also building valuable Optimer® assets with partners, aiming for future licensing revenue.   Founded in 2008, the Group listed on the London Stock Exchange AIM market in December 2021 and is headquartered in York, UK.   To register for news alerts by email go to https://aptamergroup.com/investors/investor-news-email-alerts/   This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com. RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.   END     NRASDAFEFEISEEW

Recent news on Aptamer

See all news